(Q37790671)

23 August 2017

title

EGFR and KRAS in colorectal cancer (English)

1 reference

23 August 2017

EGFR and KRAS in Colorectal Cancer (English)

0 references

1 reference

1 reference

Josep Tabernero Caturla

series ordinal

4

object named as

Josep Tabernero

1 reference

23 August 2017

Ben Markman

1

1 reference

23 August 2017

Francisco Javier Ramos

series ordinal

2

1 reference

23 August 2017

Jaume Capdevila

series ordinal

3

1 reference

23 August 2017

publication date

1 January 2010

1 reference

Advances in Clinical Chemistry

23 August 2017

2010

0 references

published in

1 reference

23 August 2017

volume

51

1 reference

23 August 2017

page(s)

71-119

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

1 reference

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Responsiveness to cetuximab without mutations in EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Ras oncogenes and their downstream targets

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

1 reference

7 January 2021

Prevalence of ras gene mutations in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Genetic alterations during colorectal-tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Prognostic significance of K-ras mutations in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Liver resection for colorectal liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Effect of fixatives and tissue processing on the content and integrity of nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phosphatidylinositol-3-OH kinase as a direct target of Ras

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Circulating mutant DNA to assess tumor dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2423%2810%2951004-7

7 January 2021

10.1016/S0065-2423(10)51004-7

Identifiers

DOI

0 references

1 reference